Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
SEC-verified vehicles of the same sponsor, predating these roles and carrying none of them. The badge counts them; the figure beside this one does not.
Mergers closed across all 3 — these vehicles and the franchise's earlier ones together.
Announced but not closed, and still hunting — again over all 3.
No closed vehicle here has both a stored price and a filed trust value to score it against.
2 vehicles on file, newest listing first
3 of 7 appear on more than one
5 people on two or more of them
Dr. Someit Sidhu is a serial biotech entrepreneur, physician, and SPAC sponsor based in London, England, who currently serves as Chairman of the Board and Chief Executive Officer of JATT II Acquisition Corp (NASDAQ: JATT), a $60 million blank-check company that priced its IPO on April 17, 2026, with Guggenheim Securities as sole bookrunner. JATT II is sponsored by JATT Ventures II L.P., of which Dr. Sidhu is a limited partner and the sole member of JATT Ventures II Ltd. The SPAC targets healthcare and healthcare-related businesses with a primary emphasis on biotechnology and broader life sciences, particularly companies applying data-driven approaches such as machine learning, computational biology, and structure-based drug design to therapeutic discovery and development. On June 29, 2026, JATT II announced a definitive business combination agreement with Talawar Therapeutics, a $120 million healthcare deal. Dr. Sidhu's board at JATT II includes Verender S. Badial, Arjun Goyal, Jonathon Kluft, and Christopher Staral, with Nicholas Fernandez serving as Chief Financial Officer.
Dr. Sidhu previously led JATT Acquisition Corp, the predecessor SPAC, as CEO and a director from its inception through its $138 million IPO on the NYSE in July 2021 and the completion of its business combination with Zura Bio Limited on March 20, 2023. That combination created an NYSE-listed biotechnology company focused on novel therapeutics for immune and inflammatory disorders, with Dr. Sidhu continuing as Co-Founder and Director of Zura Bio (Nasdaq: ZURA). He raised approximately $160 million in connection with Zura Bio's listing. On May 20, 2026, Dr. Sidhu notified Zura Bio that he would resign from its board effective May 21, 2026, with the company stating the resignation was not due to any disagreement regarding operations, policies, or practices. As of September 2024, he held approximately 3,623,319 shares of Zura Bio stock, with an estimated net worth of at least $21 million.
Beyond his SPAC activities, Dr. Sidhu has founded and led several healthcare companies. He is the founder of Khanda Therapeutics, where he has served as CEO and director since December 2025. He is also the Co-Founder and former CEO of Izana Bioscience Ltd., founded in 2017, and the Co-Founder of Pathios Therapeutics. Prior to his entrepreneurial ventures, he advised major international pharmaceutical companies as a management consultant at McKinsey & Company, where he focused on pharmaceutical R&D and portfolio strategy. Dr. Sidhu holds a Bachelor of Medicine degree from the University of Oxford, where he studied from 2007 to 2013 at Oxford Medical School. His career reflects a track record of bridging clinical expertise, strategic consulting, and capital markets to build and scale biotechnology companies, and he has been recognized as an inspiring entrepreneur who has made significant strides in the biotech industry, including speaking at events such as the OxBio Summit on career pathways in biotech.
This record is keyed to SEC CIK 0001870329 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 9 institutional-holder rows on these vehicles, under 7 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.